Outlook Therapeutics, Inc. (OTLK)
About Outlook Therapeutics, Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $1.4M
- Net income
- -$62.4M
- Total assets
- $18.6M
- Market cap
- $115.4M
- Gross margin
- 4.0%
- Operating margin
- -4744.3%
- Net margin
- -4416.2%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $1.4M
- Cost of revenue
- $1.4M
- Gross profit
- $57.2K
- Operating expenses
- $67.1M
- Operating income
- -$67.1M
- Income tax
- -$1.6M
- Net income
- -$62.4M
- EPS (basic)
- $-1.79
- EPS (diluted)
- $-1.79
Balance sheet
- Total assets
- $18.6M
- Current assets
- $17.4M
- Total liabilities
- $50.8M
- Current liabilities
- $45.8M
- Shareholders’ equity
- -$32.2M
Cash flow
- Operating cash flow
- -$51.8M
- Investing cash flow
- $6.8M
- Financing cash flow
- $45.0M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $115.4M
- EPS (diluted)
- $-1.79
- Shares outstanding
- 82.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 13, 2016
Outlook Therapeutics, Inc. (OTLK) Stock Price
- Reported a net loss of $62.4M in FY2025.
- Revenue grew 251% from FY2021 to FY2025.
- Gross margin of 4.0%, net margin -4416.2%.
- Trading 53% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Outlook Therapeutics, Inc..
Write a review
News about Outlook Therapeutics, Inc.
News & sentiment via Polygon.io
Outlook Therapeutics, Inc.: frequently asked questions
Is Outlook Therapeutics, Inc. an American company?
Outlook Therapeutics, Inc. is a US-based company headquartered in Iselin, New Jersey, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Outlook Therapeutics, Inc. headquartered?
Outlook Therapeutics, Inc. is headquartered in Iselin, New Jersey, United States.
Is Outlook Therapeutics, Inc. publicly traded?
Yes — Outlook Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol OTLK on the NASDAQ.
What does Outlook Therapeutics, Inc. do?
Outlook Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
